Peptides are everywhere right now. BPC-157 for gut healing. Ipamorelin for growth hormone. CJC-1295 for anti-aging. Your patients are asking about them, other clinics are offering them, and the wellness world is treating them like the next great frontier in functional medicine.

But before you add peptides to your practice menu, there's something you absolutely need to understand — because what looks like a gray area is actually federal law, and the FDA is actively enforcing it.

Here's the Legal Reality Nobody Is Talking About

The most important thing I can tell you is this: the vast majority of peptides being marketed for wellness have never been approved by the FDA for any human use.

That's not a technicality. That's the whole ballgame.

Under the Federal Food, Drug, and Cosmetic Act (FD&C Act), when a product is marketed with claims like "accelerate healing" or "reverse aging," it is legally classified as a drug. And because these peptides have never gone through the New Drug Application (NDA) process, they are legally considered unapproved new drugs. Selling, distributing, or administering them for human use is a direct violation of federal law — full stop.

"But I'm Prescribing Them Off-Label…"

This is the most dangerous misconception I see in the functional medicine space, and I want to be really clear here.

Off-label prescribing is not the same as prescribing an unapproved drug.

Off-label use means you're prescribing an FDA-approved drug for a condition outside its approved indication. Semaglutide (Ozempic) is a perfect example — it's FDA-approved for type 2 diabetes, but physicians can lawfully prescribe it off-label for weight loss because the drug itself has passed rigorous safety and efficacy review.

BPC-157 has never been approved for anything. There is no label to go "off" of. Prescribing it isn't off-label use — it's administering an unapproved new drug. Those are two very different things legally, and conflating them is exactly the kind of thinking that gets providers in serious trouble.

What About "Research Chemical" Disclaimers?

You've probably seen peptides sold online with fine print that says "for research purposes only — not for human consumption." The FDA has addressed this repeatedly in warning letters. When a product is clearly being marketed and dosed for human use, that disclaimer is legally meaningless. It doesn't create any protection for you as a provider, and it doesn't create any protection for the seller.

The FDA Has Moved to Close the Compounding Pathway

For a while, some providers were sourcing peptides through compounding pharmacies under the argument that they were operating within the 503A or 503B framework. That door is now largely closed.

The FDA has placed BPC-157, Ipamorelin, and several other popular peptides on its "Category 2" list of bulk drug substances — meaning they raise significant safety risks and are not eligible for use in compounding. This effectively cuts off what was one of the last semi-legitimate supply chains for these substances.

What Happens If Something Goes Wrong?

Here's where this gets very real for your practice.

If a patient is harmed by an unapproved peptide you administered or even recommended, you are exposed on multiple fronts:

Your malpractice insurance almost certainly won't cover you. Most policies exclude treatments that fall outside the standard of care or that involve illegal substances — and an unapproved new drug checks both boxes.

Your medical board can take action against you. Administering or recommending unapproved drugs is grounds for disciplinary action, including fines, license suspension, or revocation.

The FDA and DOJ are actively prosecuting. This isn't theoretical. Compounders have faced massive fines, asset forfeiture, and criminal charges for distributing unapproved peptides. Enforcement is real and it's happening now.

And if you think you can sidestep this by simply recommending that patients source their own peptides from online research sites rather than dispensing them yourself — that strategy doesn't hold up. Recommending a patient use an unregulated substance from an illicit source is still a severe breach of the standard of care. You're still the provider who made the recommendation. You still own that liability.

So What Can You Recommend?

This is where I want to shift the conversation, because the goal here isn't to scare you away from helping your patients — it's to help you do it in a way that actually protects you.

There is a clear, legal framework for recommending supplement-based wellness support under the Dietary Supplement Health and Education Act (DSHEA). Products that contain legitimate "dietary ingredients" — vitamins, minerals, amino acids, herbs, and substances derived from food sources with a history of use — can be recommended with confidence.

Collagen peptides? Legally compliant — derived from food sources with a long history of use. Creatine? Legally sold as a dietary supplement with strong research backing. Amino acids like L-Glutamine or L-Arginine? All legally sound dietary ingredients.

The key distinction is this: collagen is a food-derived substance with established status under DSHEA. Synthetic BPC-157 is not a dietary ingredient — it's a synthetic compound that falls squarely under the definition of a new drug. Calling it a supplement doesn't make it one.

When you do recommend supplements in your practice, also make sure you're using structure/function claims rather than disease claims. "Supports a healthy gut lining" is a legal claim. "Treats leaky gut" is not. That line matters.

The Bottom Line

I understand the appeal here. Peptides are generating real excitement, your patients are asking about them, and it can feel like other clinics are doing it without consequences. But every sale, injection, or recommendation involving an unapproved peptide is a legal and financial risk that simply isn't worth taking — especially when there are compliant ways to support your patients' wellness goals.

The functional medicine space is already operating in a complex regulatory environment. Your license, your practice, and your patients are too important to risk on substances the FDA has explicitly flagged as unapproved new drugs.

If you have questions about how to structure your supplement recommendations, review your current compliance posture, or understand where your practice stands on these issues — that's exactly the kind of thing we work through inside the Practice Protection Program.

This content is for informational and educational purposes only and does not constitute legal advice. Please consult with a licensed attorney in your state for advice specific to your practice.